eIF2α CRISPR/Cas9 KO Plasmid (h): sc-400199
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- eIF2α CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the eIF2α genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: eIF2α Antibody (D-3): sc-133132
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
eIF2α CRISPR/Cas9 KO Plasmid (h) | sc-400199 | 20 µg | $397.00 |
Overview
EIF2S1 encodes eukaryotic translation initiation factor 2 subunit alpha (eIF2α), a central regulator of cap-dependent translation initiation and proteostasis. Phosphorylation of eIF2α at Ser51 integrates multiple stress-sensing kinases (PERK/EIF2AK3, GCN2/EIF2AK4, PKR/EIF2AK2, and HRI/EIF2AK1) to modulate ternary complex availability, suppress global protein synthesis, and promote selective translation programs such as ATF4 within the integrated stress response. Through this pathway, eIF2α links endoplasmic reticulum stress, amino acid deprivation, viral sensing, and oxidative stress to adaptive transcriptional and translational remodeling. Dysregulated eIF2α signaling is implicated in cancer cell stress tolerance, neurodegenerative protein aggregation phenotypes, and metabolic and inflammatory states via altered translational control and stress granule dynamics.
eIF2α CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the EIF2S1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the EIF2S1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the EIF2S1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish eIF2α protein expression.
This CRISPR knockout system enables efficient generation of EIF2S1-deficient cell models for investigation of eIF2α signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting EIF2S1 exon(s) critical for eIF2α function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple EIF2S1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by eIF2α CRISPR/Cas9 KO Plasmid (h) and eIF2α CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the EIF2S1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by eIF2α HDR Plasmid (h) and eIF2α HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by EIF2S1 homology arms to support homology-directed repair at defined EIF2S1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.